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Experimental evidence suggests a number of 
pathologic and electrophysiologic mechantsms that 
may help initiate ventricular arrhythmias accom- 
panying myocardial ischemla and infarction. Early 
and late phase events are associated with reentry 
or an enhancement of focal mechanisms, or both. 
These can initiate ventricular tachycardia (VT) or 
ventricular fibrillation (VF), or both. The presence 
of dtstinct mechanisms that may inttiate and main- 
tain life-threatening dysrhythmias early in myo- 
cardial ischemia suggest different pharmacologic 
approaches for their prevention or suppression. 
Another consideration concerns patients subjected 
to coronary artery angioplasty or thrombolyttc 
therapy and the development of arrhythmias asso- 
ciated with reperfuslon of the once ischemic myo- 
cardium. The electrophystologic mechanisms as- 
sociated with reperfusion arrhythmias are unknown, 
and little is known about appropriate therapy for 
each episode of cardiac dysrhythmta. 
Ventricular extrasystoles or VT usually precedes 
VF. These premonitory arrhythmias are poor criteria 
for the institution of antiarrhythmic drug therapy, 
because VF develops within 1 to 10 minutes after 
the appearance of the rhythmic dtsturbances. Borne 
authorities suggest that all patfents with acute 
myocardial infarction should receive prophylactic 
antiarrhythmic therapy, because warning arrhyth- 
mias either do not occur at all or provide insufficient 
time to intervene pharmacologically. 
Many of the new class I antiarrhythmic agents 
effectively reduce the frequency of premature 
ventricular depolarizations, but lack specific anti- 
fibrillatory activity. However, the recent introduction 
of bretylium into clinical cardiology opens a new 
approach to preventing life-threatening ventricular 
dysrhythmias. Along with other members of class 
III, bretyllum exerts different cardiac electrophysi- 
ologic effects than do the other 3 classes of drugs. 
Bretylium has been designated as class III because 
it increases the action potential duration and 
prolongs the effective refractory period. The other 
class III drugs, including amiodarone, sotalol, clofi- 
lium and pranolium, experimentally prevent the 
establishment of a reentry pathway that can initiate 
VF. Bretylium along with these other class III agents 
is primarily anttfibrillatory rather than antiarrhythmlc. 
Thus, antiarrhythmic agents that reduce the fre- 
quency and complexity of premature ventricular 
depolarizations are not necessarily antifibrillatory. 
It is necessary to reorient our thinking about how 
pharmacologic interventions may influence the 
course of events in patients at risk of developing 
life-threatening ventricular arrhythmias. Because 
the lethal event is most often associated with VF, it 
may be sufficient to have an agent that protects 
against this electrophysiologic disorder even though 
it does not completely prevent or suppress other 
ventricular arrhythmias. 
(Am J Cardiol 1984;54:14A-19A) 
The most catastrophic event that can happen to a pa- 
tient with acute myocardial infarction (MI) is the de- 
velopment of primary ventricular fibrillation (VF), 
which is often associated with previous electrocardio- 
graphic evidence of ventricular electrical instability as 
demonstrated by the occurrence of premature ventric- 
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ular complexes or episodes of ventricular tachyar- 
rhythmia, or both.i Because this discussion will focus 
on patients with coronary artery disease, the term 
sudden coronary death becomes more appropriate than 
the broader concept of sudden cardiac death. Within 
this context, an effort will be made to provide a rational 
basis for the selection of drug therapy for the prevention 
of recurrent episodes of life-threatening ventricular 
tachycardia (VT) and VF. Effective therapeutic inter- 
ventions would be most wanted for those individuals 
who are at high risk as determined by the presence of 
coronary artery disease and left ventricular character- 
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istics associated with :recurrent episodes of ventricular 
tachyarrhythmia. 
proposed for verapamil, which prolongs conduction time 
in the ischemic myocardial region, but not in the normal 
The Necessary Substrate for Ventricular 
Tachyarrhythmia and Ventricular Fibrillation 
Myocardial ischemia and MI commonly are accom- 
panied by the development of ventricular arrhythmias 
or tachyarrhythmias, or both, because of alterations in 
the cellular electrophysiologic characteristics of those 
myocardial cells involved in the ischemic process.2 The 
underlying alterations in cellular electrophysiologic 
aspects can further be influenced by the activity of the 
autonomic nervous syrstem.3y4 
Studies by Waldo and Kaisers and Boineau and Coxe 
demonstrated that the period immediately after acute 
coronary artery occlusion was associated with transient 
or sustained periods of continuous electrical activity, 
or local fibrillation, within the ischemic or infarcted 
myocardium, or both. Persistence of continuous elec- 
trical activity beyond the T wave of the preceding im- 
pulse almost always was associated with ventricular 
extrasystoles. Therefore, the presence of sustained 
electrical diastolic activity or localized fibrillation may 
provoke the development of VT or VF. The implication 
is that persistent diastolic activity within the area of 
ischemic myocardial injury spreads to the remainder of 
the ventricle, resulting in abnormal rhythm. The elec- 
trophysiologic propert:ies of the ischemic myocardium, 
such as enhanced threshold of excitability, shortened 
refractory period, decreased conduction velocity and 
increased inhomogeneity of the recovery of excitability, 
provided a suitable substrate for initiation and per- 
petuation of VF.7-11 The localized areas of sustained 
excitation function as a source of reentrant activity12J3 
and suggest that a potential site of action for an anti- 
arrhythmic drug could be located within the ischemic 
region or the normal myocardium so as to result in 
electrophysiologic alterations that would decrease the 
disparity between the 2 regions or prevent the contin- 
uous excitation within the ischemic zone from entering 
the surrounding normal myocardium. 
Recent data support the concept that early arrhyth- 
mias associated with coronary artery occlusion, and 
most likely the development of VF, are due to reentry 
mechanism, whereas late occurring arrhythmias are 
more likely the result of enhanced or abnormal auto- 
maticity.12-l7 
The electrophysiologic effects of lidocaine have been 
studied in the in situ canine heart in which epicardial 
electrograms were recorded from the normal and 
ischemic zones.ls Lidocaine delayed activation and 
prolonged the effective refractory period of the infarcted 
zone of the heart, without affecting these parameters 
in the normal myocardial region; the drug primarily 
decreased the disparity in the effective refractory pe- 
riods of the 2 myocardial regions. Subsequent studieslg 
showed that lidocaine affects intraventricular conduc- 
tion as do quinidine and procainamide. Therefore, lid- 
ocaine may abort reentrant ventricular arrhythmias by 
depressing the conduction velocity within the region of 
myocardial injury to the point of extinction of the 
reentrant wave-front. A similar mechanism has been 
zone.2o 
More recently, the technique of programmed elec- 
trical stimulation in the chronically ischemic canine 
heart has been used to assess the ability of disopyramide 
to prevent reentrant tachyarrhythmias2l The drug was 
effective only at a plasma concentration which exceeded 
that usually considered to be therapeutic. These find- 
ings were not unlike those of Horowitz et a122 who used 
programmed electrical stimulation to induce reentrant 
rhythms in patients with recurrent episodes of VT and 
in whom the effective plasma concentrations of diso- 
pyramide were well beyond the upper limit of what is 
considered the therapeutic range. 
The results of such studies might be interpreted as 
suggesting that currently available class I antiar- 
rhythmic drugs might have the ability to suppress or 
prevent reentrant ventricular rhythms, but they will 
only do so at dosages that will not be tolerated by most 
patients. The latter point is illustrated by the results of 
Lie et a123 who studied 212 patients with acute MI 
randomized by 2 treatment groups. Among 107 patients 
receiving lidocaine (lOO-mg loading dose followed by 3 
mg/min for 48 hours), no episode of primary VF oc- 
curred. This result contrasted with 9 episodes of pri- 
mary VF among 105 patients receiving placebo (5% 
dextrose and water). Side effects occurred in 15% of the 
patients treated with lidocaine and were more common 
in older patients. 
The major electrophysiologic effects of the class I 
antiarrhythmic drugs in suppressing reentrant rhythms 
are due to their ability to convert unidirectional block 
into bidirectional block by slowing conduction in both 
normal and depressed myocardial regions. The class I 
drugs also prolong the effective refractory period. 
Therefore, it is theoretically possible that class I anti- 
arrhythmic agents might have the potential to facilitate 
the induction of reentrant rhythms, depending on the 
balance of their effects on conduction velocity and re- 
fractoriness in normal and ischemic myocardium.21T24 
Class I antiarrhythmic drugs perhaps will be found to 
prevent recurrent episodes of VT and prevent VF only 
at plasma concentrations that are not tolerated by a 
significant number of patients. Failure of previous 
clinical trials to provide clear-cut evidence for a re- 
duction in the frequency of primary VF despite a re- 
duction in the frequency or complexity of premature 
ventricular complexes may be related to the finding that 
higher plasma concentrations of the class I drugs are 
required to prevent reentrant rhythms that lead to 
VF. 
Electrophysiologic abnormalities can be demon- 
strated in many patients who have survived an episode 
of out-of-hospital cardiac arrest not associated with 
acute MI.zkss The continued presence of an electrically 
unstable myocardial substrate is suggested by the 
finding that VT will develop in 81% of such patients in 
response to programmed electrical stimulation. The 
ability to induce VT by electrical stimulation is rarely, 
if ever, observed in patients who do not possess under- 
lying heart disease, 29 thus emphasizing the importance 
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of a vulnerable substrate for the initiation and main- 
tenance of lethal tachyarrhythmia. 
The importance of the presence of a vulnerable 
myocardial substrate for the development of sudden 
coronary death has been emphasized by the observation 
of Schuster and Bulkley.30 They identified 2 groups with 
early postinfarction angina: those with ischemia at a 
distance and those with ischemia in the infarct zone. 
Patients with ischemia at a distance constitute a subset 
of hemodynamically stable patients who face an unex- 
pectedly high mortality because of a persistently 
ischemic myocardium which provides the proper sub- 
strate for the genesis of reentrant rhythms and the de- 
velopment of VF. 
Evaluating the Antiarrhythmic vs the 
Antifibrillatory Action of Pharmacologic 
Interventions 
The presence of a vulnerable substrate needed for the 
genesis of life-threatening tachyarrhythmias is sup- 
ported by the use of programmed electrical stimulation 
to elicit ventricular arrhythmias, as already discussed 
herein, and has led to the use of provocative testing 
procedures in the identification of pharmacologic agents 
for prophylactic management of patients determined 
to be at high risk of sudden coronary death. In most 
patients with recurrent sustained VT, the arrhythmia 
occurs sporadically; therefore, empiric selection of 
therapy is marked by fallibility in both the choice and 
the dose of antiarrhythmic agent. Electrophysiologic 
testing is believed to provide an objective basis on which 
rational pharmacologic therapy can be selected,al be- 
cause recurrent VT can be reproducibly initiated by 
programmed electrical stimulation in most patients 
with chronic ischemic heart disease. 
The use of an electrophysiologic protocol for drug 
selection is based on several assumptions: (1) the 
tachycardia produced in the laboratory by programmed 
stimulation is identical to clinical tachyarrhythmia; (2) 
the response to drug therapy in the laboratory predicts 
the clinical response; and (3) the ability to prevent 
electrically induced VT by drug treatment predicts the 
inability of the heart to develop VF, especially if an 
ischemic episode superimposes on a vulnerable sub- 
strate. Is the prevention of electrically induced ar- 
rhythmias by drug therapy synonomous with the pre- 
vention of sudden coronary death? Probably not. 
Although the first and second assumptions may be es- 
tablished, the third is not, because an acute ischemic 
episode is not part of the testing procedure. The true 
efficacy of an intervention can only be determined by 
looking at its potential to prevent sudden coronary 
death. Programmed electrical stimulation and acute 
pharmacologic testing may not be valuable in helping 
to identify those at risk of sudden coronary death and 
in establishing treatment regimens. The identification 
of a truly effective agent will be determined by its ability 
to prevent VF, an end point seldom achieved during 
provocative testing procedures. It may also be true that 
a drug fails to prevent the initiation of tachyarrhythmia 
by programmed electrical stimulation may still suc- 
cessfully prevent a spontaneous recurrence. This would 
be especially true of those agents that accumulate in 
myocardial tissue over time and show little correlation 
between concentration of drug in the plasma and ther- 
apeutic efficacy. 
Considering the magnitude of the problem of sudden 
coronary death, there is a need for an intensive program 
aimed at the development of new therapeutic inter- 
ventions as the only practical approach to the reduction 
in mortality among those identified to be at risk. The 
ideal antiarrhythmic, or to be more precise, antifibril- 
latory agent, does not exist. Despite extensive clinical 
studies, it is not possible to demonstrate that 11 of the 
newer pharmacologic agents possess any promise as 
being the ideal agent for the prevention of sudden cor- 
onary death. May et a132 recently reviewed the results 
of 14 clinical trials involving 3,625 patients with docu- 
mented MI who were treated with 1 of 4 antiarrhythmic 
drugs including quinidine, disopyramide, procainamide 
and lidocaine. Despite the fact that each agent has been 
reported to suppress ventricular arrhythmias in the 
acute phase of MI, and lidocaine may reduce the inci- 
dence of in-hospital VF, not 1 of the trials has demon- 
strated that suppression of ventricular premature 
complexes is accompanied by a statistically significant 
reduction in overall mortality. 
Ruskin et al33 employed electrophysiologic testing in 
98 patients who had survived an episode of cardiac ar- 
rest. Six of the 98 patients had been taking antiar- 
rhythmic drugs at the time of cardiac arrest. Before the 
administration of antiarrhythmic therapy, no patient 
had a documented episode of VT or symptoms sugges- 
tive of it. After therapy was initiated, however, cardiac 
arrest occurred with documented VF or VT within 3 to 
5 months in the 6 patients. Electrophysiologic testing 
demonstrated that these patients were more susceptible 
to inducible VT while taking antiarrhytbmic drugs than 
in the absence of drug therapy. When the drugs were 
withdrawn for 48 hours, no patient responded to elec- 
trophysiologic testing with the induction of ventricular 
tachyarrhythmias. The clinical implication of this study 
is significant and provides strong circumstantial evi- 
dence that antiarrhythmic drugs can contribute to ep- 
isodes of cardiac arrest. 
The recurrence rate of sudden death is extremly high 
(30 to 40%), especially among those whose cardiac arrest 
was not associated with acute MI. Treatment with an 
antiarrhythmic agent would seem essential. In such 
patients, programmed electrical stimulation can often 
induce sustained VT or VF, or both. What is unclear, 
however, is whether a drug that prevents electrically 
induced arrhythmias in a patient rescued from cardiac 
arrest will also be effective in preventing spontaneous 
recurrence of sudden coronary death. Roy et alN re- 
ported their long-term experience after electrophysio- 
logic testing in 119 patients resuscitated from cardiac 
arrest. Repeat electrophysiologic testing was performed 
in 60 patients after initiating therapy and 41 were not 
inducible. The rate of recurrent sudden death in the 41 
patients over a follow-up period of 17 months was 15%. 
The long-term recurrence rate of sudden death in pa- 
tients who remained inducible was 21% (4 of 19). There 
were 47 sudden death survivors in whom sustained ar- 
rhythmias could not be induced. Ten of 29 (34%) treated 
patients had recurrent sudden death as did 5 of 18 who 
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received no specific antiarrhythmic therapy. There were 
9 patients who received amiodarone and in whom 
catheter-induced arrhythmias could not be prevented 
when reevaluated after acute.administration. Only 1 of 
the 9 patients on amiodarone therapy experienced re- 
current sudden deatlh. These studies suggest that suc- 
cessful abolition of inlduced arrhythmias is a meaningful 
way of assessing drug efficacy and that amiodarone 
might be reserved for patients whose condition is re- 
fractory to standard antiarrhythmic agents. 
Invasive electroph,ysiologic testing currently may be 
the best approach in selecting effective antiarrhythmic 
therapy in patients who have had a life-threatening 
ventricular arrhythmia. The appropriate means of de- 
termining therapy in patients who are at high risk of 
sudden death but who only demonstrate nonsustained 
VT and complex ventricular ectopic depolarizations 
remains uncertain. Spielman et aP5 reported that 
electrophysiologie-testing ismore effective than em- 
pirical drug selection in high-risk patients who have not 
manifested recurrent VT or out-of-hospital cardiac 
arrest. 
Antiarrhythmic vs Antifibrillatory Drugs 
There has been an “explosive” appearance of new 
ant&rhythmic agents (Table I) that are reported to be 
effective in reducing the frequency of premature ven- 
tricular complexes, but most lack specificity with re- 
spect to antifibrillatory activity. Thus, current proce- 
dures used to identify an agent capable of preventing 
sudden cardiac .death may be inadequate if the end 
point is something other than VF. The antiarrhythmic 
drugs currently available in the United States for the 
long-term management of patients with life-threatening 
arrhythmias are quinidine, procainamide, disopyram- 
ide, propranolol, timolol, metoprolol and phenytoin. 
None is considered entirely suitable for long-term 
prophylactic use in the prevention of sudden coronary 
death. Of the new class I agents including aprindine, 
tocainide, mexiletine, encainide, ethmosin, flecainide 
and pirmenol, none is known specifically to prevent VF 
in either the experimental animal or man. There are 
limited published preclinical data with respect to many 
of these agents, and already several are proving to have 
serious toxic effects. 
Studies recently reviewed by Singh and Venkateshss 
demonstrate a clear rationale for the prophylactic use 
of fl-adrenergic receptor blocking agents (propranolol 
and timolol) in subsets of patients with ischemic heart 
disease for the purpose of reducing the incidence of 
sudden death and the recurrence of MI. Although the 
beneficial result is attributed to the establishment of 
P-adrenergic receptor blockade, the exact mechanism 
of the salutary effect is not known. The antiischemic 
effects that accrue as a result of inhibiting adrenergic 
responses of cardiac @receptors may serve to prevent 
the initiating triggering event from acting on a vulner- 
able myocardial substrate. Therefore, a primary anti- 
arrhythmic or antifibrillatory action may not be present 
in many members of this class, despite their ability to 
reduce the incidence of lethal arrhythmic events in 
patients with ischemic heart disease. Despite their 
demonstrated efficacy in reducing morbidity in survi- 
TABLE I Classification of Antiarrhythmic Drugs 
Class Drugs 





Aprindine, encainide, lorcainide, flecainide, ethmozin, 
propafenone, pirmenol 
Propranolol, timolol, atenolol, metoprolol, nadolol 
Bretylium: sotalol, amiodarone, clofilium, pranolium 
Verapamll, diltiazem, bepridil 
vors of acute MI, therapy with the /3-adrenergic receptor 
blocking agents may not be applicable to all survivors 
with acute MI or to those patients rescued from sudden 
coronary death but in whom MI has not occurred. De- 
spite dramatic progress, the need for alternative phar- 
macologic interventions for patients at risk of sudden 
coronary death is clearly recognized. 
The recent introduction of bretylium into clinical 
cardiology has suggested a new approach to the pre- 
vention of life-threatening ventricular arrhythmias. The 
precise mechanism by which bretylium produces its 
antifibrillatory effect is unknown, but its cellular elec- 
trophysiologic effects differ significantly from those of 
the class I and class II antidysrhythmic drugs. Bretyl- 
ium has been classified as belonging to a group of agents 
that are placed in class III because they have the prop- 
erty of increasing the ventricular action potential du- 
ration and prolonging the effective refractory period. 
Others considered to be class III antidysrhythmic agents 
include amiodarone, sotalol, clofilium and prano- 
lium.37 
Indirect and Direct Cardiac Actions of Bretylium 
Alterations in adrenergic neuronal function: The 
acute single dose of bretylium leads to a biphasic car- 
diovascular response in both experimental animals and 
man.384o The initial displacement of norepinephrine 
from adrenergic nerve terminals results in an increase 
in arterial blood pressure, vascular resistance and heart 
rate and may augment the frequency of ventricular 
premature complexes. The initial response begins to 
dissipate by 20 tc 30 minutes and blood pressure, vas- 
cular resistance and heart rate begin to decrease as pe- 
ripheral sympathetic tone decreases secondary to the 
adrenergic neuronal blocking effects of bretylium 
(chemical sympathectomy). The latter effect predom- 
inates during the chronic phase of therapy and may be 
circumvented by the previous administration of a tri- 
cyclic antidepressant drug, e.g., protriptyline or dox- 
epin, which effectively blocks the uptake mechanism 
in adrenergic neurons, thereby preventing bretylium 
from gainii access to the adrenergic nerves. Therefore, 
the catecholamine release and subsequent sympatho- 
lytic effects of bretylium can be prevented without af- 
fecting the electrophysiologic effects of the quaternary 
amine on the heart.4cr41 The complicating effects of 
catecholamine release can be minimized or prevented 
by pretreatment with a tricyclic antidepressant40p41 or 
by the previous administration of a /3-adrenergic re- 
ceptor antagonist.42 
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Direct Electrophysiologic Effects of Bretylium 
The direct electrophysiologic effects of bretylium 
resulting in prolongation of the ventricular refractory 
period can be demonstrated with long-term drug ad- 
ministration and in the absence of endogenous cate- 
cholamine release.43 The direct electrophysiologic and 
antifibrillatory effects of bretylium were noted to par- 
allel the myocardial rather than the serum concentra- 
tions of the drug, with the peak response occurring 3 to 
6 hours after intravenous administration. Our data 
suggest that the kinetics of the electrophysiologic and 
antifibrillatory effects of bretylium parallel those of 
drug accumulation in myocardial tissue, whereas the 
kinetics of catecholamine release and serum concen- 
tration of the drug are dissimilar. These studies dem- 
onstrate the marked time and dose-dependent differ- 
ences in response to bretylium. The delayed response 
in the increase in the ventricular refractory period and 
fibrillation threshold with small doses might be con- 
verted to a more immediate response by a larger initial 
dose which results in a more rapid accumulation of the 
drug in myocardial tissue. The limitation in the rate of 
administration of bretylium is due to the concomitant 
effects on the adrenergic neuronal stores of norepi- 
nephrine. 
The electrophysiologic effects of intravenous brety- 
lium on the conduction of premature impulses and ex- 
citation threshold in the normal and ischemic 
myocardium have been described.44F45 There was a 
significant delay in the conduction of impulses from 
normal myocardial tissue to the border of the ischemic 
heart muscle and a decrease in the disparity between 
excitation thresholds of adjoining ischemic and normal 
myocardial regions. As noted by others,4244 the elec- 
trophysiologic effects of bretylium were delayed in their 
appearance, once again suggesting the need for the drug 
to accumulate in myocardial tissue. However, the effects 
of bretylium on the VF threshold and defibrillation 
threshold occur within minutes of administration. 
The most prominent electrophysiologic actions of 
bretylium are an increase in the threshold current re- 
quired to induce VF and a prolongation in the ventric- 
ular effective refractory period,46-50 an effect that is 
more prominent than that observed with other currently 
available antiarrhythmic drugs grouped under class 
I.47-5o A most interesting observation is the spontaneous 
conversion of VF to sinus rhythm after the adminis- 
tration of bretylium.sl Chemical defibrillation has not 
been observed with other antiarrhythmic agents and is 
a property possessed by bretylium and other investi- 
gational drugs grouped as class III antiarrhythmic 
agents.37vs2 The ability of bretylium to exert an antifi- 
brillatory effect is unlikely to be a result of its actions 
on the sympathetic nervous system, because guaneth- 
idine, a compound that exerts similar actions on the 
sympathetic nervous system, does not possess an anti- 
fibrillatory action when studied in the experimental 
animal.48,53 Bretylium is equally as effective in the heart 
of reserpine-treated animals53 and in the denervated 
heart54 as it is in the normal heart. Several currently 
available drugs (quinidine, lidocaine, phenytoin, diso- 
pyramide, procainamide and propranolol) are reported 
to increase the current required to achieve ventricular 
defibrillation in the experimental anima1.55 However, 
bretylium decreases the electrical threshold for suc- 
cessful defibrillation.56 
Haynes et a157 compared the immediate and short- 
term effects of bretylium and lidocaine in the manage- 
ment of 146 victims of out-of-hospital VF in a 
randomized blinded trial. The administration of 
bretylium (500 mg intravenously) or lidocaine (100 mg 
intravenously) followed by resuscitative measures re- 
sulted in the development of an organized cardiac 
rhythm in most patients (89 and 93% in the bretylium 
and lidocaine groups, repsectively). The lidocaine- 
treated group showed a slightly greater tendency 
towards conversion to asystole (46 vs 34%), whereas 
bretylium-treated patients had a somewhat greater 
tendency towards recurrent VF (49 vs 39%). Chemical 
defibrillation was not observed with either of the drug 
treatments. There was no difference with respect to the 
number of patients successfully defibrillated in each of 
the groups. Therefore, the investigators did not observe 
any significant differences between the 2 groups of pa- 
tients in the response to defibrillation, in resuscitation 
or in mortality. 
Nowak et a1s8 conducted a randomized double-blind 
study comparing bretylium with saline solution (in 
addition to Advanced Cardiac Life Support protocol 
drugs and procedures) as a first-line drug in patients 
with cardiopulmonary arrest. They concluded that the 
aggressive use of bretylium (10 mg/kg) as a first-line 
agent in the treatment of out-of-hospital VF signifi- 
cantly increases the chances for successful resuscitation. 
Furthermore, the administration of bretylium followed 
by lidocaine reduced the incidence of recurrent VF. 
The observation that VF develops in 40% of patients 
with acute MI with significant warning arrhythmias 
suggests that an effective antiarrhythmic drug should 
be employed as a routine prophylactic measure. Clinical 
studies in the setting of acute MI provide convincing 
evidence that bretylium is effective in reducing the in- 
cidence of VF.59-63 
Prospects for the Future 
There has been substantial progress in recent years 
with respect to identifying subsets of patients who are 
at risk of sudden coronary death. Both surgical and 
electrical means of preventing sudden death in the most 
difficult-to-manage patient groups have been attempted 
with impressive results. However, a critical need re- 
mains for the development of more reliable and effective 
therapeutic agents capable of preventing VF. The re- 
sults being reported with amiodarone,s4965 clofilium66 
and sotalo1,s796s all members of class III; suggest that 
these agents have electrophysiologic effects that will 
prevent induction of a reentrant rhythm and develop- 
ment of a lethal arrhythmia when a triggering event is 
superimposed on the vulnerable substrate of an ische- 
mic myocardium. 
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